Chemed Co. (NYSE:CHE – Get Free Report) CFO David Patrick Williams sold 6,000 shares of the business’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $583.85, for a total value of $3,503,100.00. Following the sale, the chief financial officer now directly owns 15,826 shares of the company’s stock, valued at approximately $9,240,010.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Chemed Stock Down 0.5 %
Shares of NYSE CHE opened at $579.77 on Friday. The stock’s 50 day moving average price is $524.69 and its two-hundred day moving average price is $531.56. Chemed Co. has a 52-week low of $481.99 and a 52-week high of $590.00. The stock has a market capitalization of $8.73 billion, a P/E ratio of 35.90, a PEG ratio of 3.38 and a beta of 0.49.
Chemed (NYSE:CHE – Get Free Report) last announced its quarterly earnings data on Wednesday, October 25th. The company reported $5.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.92 by $0.40. Chemed had a return on equity of 32.87% and a net margin of 10.99%. The firm had revenue of $564.53 million for the quarter, compared to analysts’ expectations of $558.42 million. During the same quarter in the prior year, the firm posted $4.74 earnings per share. Chemed’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, analysts anticipate that Chemed Co. will post 19.3 EPS for the current year.
Chemed Dividend Announcement
Institutional Trading of Chemed
A number of institutional investors and hedge funds have recently made changes to their positions in CHE. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Chemed by 400.0% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 75 shares of the company’s stock worth $40,000 after purchasing an additional 60 shares during the period. Janiczek Wealth Management LLC grew its holdings in Chemed by 75.6% in the 2nd quarter. Janiczek Wealth Management LLC now owns 79 shares of the company’s stock worth $43,000 after buying an additional 34 shares in the last quarter. Blume Capital Management Inc. bought a new position in Chemed in the 2nd quarter worth approximately $43,000. Altshuler Shaham Ltd grew its holdings in Chemed by 60.8% in the 1st quarter. Altshuler Shaham Ltd now owns 82 shares of the company’s stock worth $44,000 after buying an additional 31 shares in the last quarter. Finally, Larson Financial Group LLC bought a new position in Chemed in the 3rd quarter worth approximately $44,000. 94.25% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the company. StockNews.com assumed coverage on Chemed in a research report on Thursday, October 5th. They issued a “buy” rating for the company. Royal Bank of Canada upped their target price on Chemed from $576.00 to $604.00 and gave the stock an “outperform” rating in a research report on Monday, October 30th.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
- Five stocks we like better than Chemed
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Institutional activity provides a bottom for gaming stocks
- What Makes a Stock a Good Dividend Stock?
- Coca-Cola EuroPacific Partners is a tasty play on Coke
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 reasons Qualcomm might be the easiest buy this month
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.